Erica DiNapoli


Chasing Survival Benefit With Novel Systemic Strategies in Early-Stage NSCLC

March 11th 2021

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Nanoliposomal Irinotecan Possesses Potential to Shake Up Pancreatic Cancer Paradigm

February 19th 2021

Reema A. Patel, MD, discusses the potential for nanoliposomal irinotecan in pancreatic cancer and other emerging approaches under exploration.

Grothey Spotlights Personalized Approaches Shaking Up CRC Care Continuum

February 10th 2021

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

Hanhan Highlights How Robotic Techniques Have Shifted Surgical Care in Lung Cancer

February 4th 2021

Ziad Hanhan MD, MPH, FACS, highlights the evolution of surgery in the field of lung cancer, the advantages associated with robotic techniques, and the crucial role of the surgeon in determining eligibility for these approaches.

Metastatic Prostate Cancer Paradigm Flourishes With Recent Progress

February 1st 2021

Data from 3 pivotal trials—PROfound, CARD, and HERO—have served to propel the metastatic prostate cancer treatment paradigm forward.

BTK Combos Seek to Raise the Bar in CLL Treatment Paradigm

January 27th 2021

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

Hormonal Agents Improve Survival in mCSPC, but Novel Targets Are Needed For Further Drug Development

January 26th 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Emerging Strategies Seek to Build on Radiation Benefits in Lung Cancer

January 19th 2021

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.